Tenax Therapeutics Inc (TENX) - News Archive

Tenax Therapeutics, a biopharmaceutical company focused on developing innovative therapies for pulmonary hypertension and heart failure, has announced the expansion of its Phase 3 LEVEL program. This initiative includes...

Tenax Therapeutics Secures $25 Million in Private Placement: A Boost for Cardiopulmonary InnovationIn a strategic financial maneuver, Tenax Therapeutics, Inc. (Nasdaq: TENX) has announced the successful agreement of a s...

In a major breakthrough for the field of cardiovascular and pulmonary medicine, Tenax Therapeutics, a Phase 3, development-stage pharmaceutical company, has announced a significant expansion of its global development, c...

In a major stride towards combatting the debilitating heart condition known as Heart Failure with Preserved Ejection Fraction (HFpEF), Tenax Therapeutics has successfully enrolled the first patient in their groundbreaki...

Chapel Hill-based specialty pharmaceutical company Tenax Therapeutics, Inc. (Nasdaq: TENX) has recently announced a significant strategic move that will reshape its capital structure and potentially open new avenues for...

Tenax Therapeutics, a leading specialty pharmaceutical company catering to unmet medical needs in cardiovascular and pulmonary diseases, has recently appointed renowned cardiologist and academician, Dr. Javed Butler, to...